Polycystic Ovary Syndrome (PCOS) Cell Models for Research

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, with a global prevalence estimated at 8-13% depending on the diagnostic criteria used (WHO, 2023). It is a leading cause of anovulatory infertility and is associated with metabolic comorbidities such as type 2 diabetes, cardiovascular disease, and endometrial cancer. The exact etiology remains unclear, but it involves a complex interplay of genetic, hormonal, and environmental factors. PCOS significantly impacts quality of life and poses a substantial economic burden on healthcare systems.

PCOS is an ideal model for studying gene-environment interactions, hormonal regulation, and metabolic dysfunction. Its heterogeneity (phenotypes A-D) allows for subtype-specific mechanistic studies. Public datasets such as GEO and the PCOS Knowledge Base provide transcriptomic and epigenetic data from patient samples and cell models. Key open questions include the molecular drivers of hyperandrogenism, insulin resistance, and follicular arrest, which can be addressed using gene-edited cell models.

While PCOS is not a cancer, it increases the risk of endometrial cancer. The key pathways involved in PCOS pathogenesis include:

• • Androgen signaling: Excess androgen production in theca cells, driven by dysregulated steroidogenesis.
• • Insulin signaling: Insulin resistance leads to compensatory hyperinsulinemia, which stimulates ovarian androgen production.
• • Gonadotropin signaling: Abnormal LH/FSH ratio disrupts folliculogenesis.
• • Inflammatory pathways: Chronic low-grade inflammation contributes to metabolic and ovarian dysfunction.

PCOS is a polygenic disorder, but certain genes show consistent alterations. The table below summarizes key genes implicated in PCOS susceptibility and pathogenesis (data from GWAS and candidate gene studies, as curated in NCBI Gene and ClinVar).

Key signaling networks deregulated in PCOS include:

• • PI3K/AKT pathway: Insulin resistance impairs this pathway, leading to metabolic dysfunction.
• • MAPK/ERK pathway: Involved in granulosa cell proliferation and differentiation.
• • Wnt/β-catenin pathway: Regulates follicular development and is dysregulated in PCOS.
• • TGF-β pathway: Affects ovarian fibrosis and follicular arrest.
• • Key nodes include:
• • PI3K (PIK3CA, PIK3R1)
• • AKT (AKT1, AKT2)
• • ERK (MAPK1, MAPK3)
• • β-catenin (CTNNB1)
• • SMADs (SMAD2, SMAD3)

Common cell lines used in PCOS research include:

Organoids derived from ovarian tissue or induced pluripotent stem cells (iPSCs) offer a more physiologically relevant model, recapitulating follicular structure and hormonal responses.

Animal models for PCOS include:

• • Prenatal androgen exposure: Female offspring develop PCOS-like features (e.g., hyperandrogenism, follicular cysts).
• • Letrozole-induced: Chronic letrozole administration induces PCOS-like phenotype in rodents.
• • Genetic models: Knockout or knock-in mice for genes like Lhcgr, Fshr, or Cyp19a1.
• • PDX models: Patient-derived xenografts of ovarian tissue or tumors, though less common for PCOS.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in PCOS-associated genes. These models are invaluable for studying gene function and drug responses. Examples include:

• • LHCGR knockout KGN cells: To study the role of LH receptor in steroidogenesis.
• • CYP19A1 knock-in reporter lines: To monitor aromatase expression and activity.
• • INSR knockout granulosa cells: To model insulin resistance.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and validated models. These can be custom-generated to meet specific research needs.

Knockout and knock-in cell lines are used to validate the functional impact of genetic variants identified in PCOS GWAS. For example, knocking out DENND1A in theca cells can confirm its role in androgen biosynthesis. Similarly, introducing a specific SNP into a cell line using CRISPR base editing can assess its effect on gene expression and cellular phenotype.

Isogenic pairs (e.g., wild-type vs. knockout) are used in high-throughput screens to identify compounds that selectively target mutant cells. For instance, screening for drugs that inhibit androgen production in LHCGR knockout cells can reveal novel therapeutic targets. Gene-edited models also help study resistance mechanisms to existing treatments like metformin or anti-androgens.

CRISPR-based synthetic lethality screens can identify genes that are essential only in PCOS-specific genetic backgrounds. For example, knocking out a gene in combination with a PCOS-associated mutation may reveal vulnerabilities that can be exploited for therapy. These screens also aid in discovering biomarkers for early diagnosis or patient stratification.